Rise of multi-resistant urinary tract infections

BJU International

Volumn 110, Issue 3, 2012, Pages 300-301

  King, Thomas ^a   Abedin, Asad ^a   Belal, Mohammed ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; BETA LACTAMASE CTX M; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; COLISTIN; DORIPENEM; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN; IMIPENEM; MEROPENEM; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE;

BACTEREMIA; BACTERIAL STRAIN; DRUG EFFICACY; ENTEROBACTER; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; KLEBSIELLA; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NONHUMAN; NOTE; PLASMID; PREVALENCE; PRIORITY JOURNAL; PROTEUS; URINARY TRACT INFECTION;

DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE INFECTIONS; HUMANS; URINARY TRACT INFECTIONS;

EID: 84863727157     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11142.x     Document Type: Note

References (15)

1. Foxman B,. The epidemiology of urinary tract infection. Nat Rev Urol 2010; 7: 653-60
2. Abraham EP, Chain E,. An enzyme from bacteria able to destroy penicillin. Nature 1940; 46: 837-837
3. Livermore D,. Has the era of untreatable infections arrived? J Antimicrob Chemother 2009; 64 (Suppl.): i29-136
4. Hoban D, Nicolle L, Hawser S, Bouchillon S, Badal R,. Antimicrobial susceptibility of global inpatient urinary tract isolates of Escherichia coli: results of the study for monitoring antimicrobial resistance trends (SMART) program: 2009-2010. Diagn Microbiol Infect Dis 2011; 70: 507-11
5. Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S,. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983; 11: 315-7 (Pubitemid 14213754)
6. Bean D, Krahe D, Wareham D,. Antimicrobial resistance in community and nosocomial Escherichia coli urinary tract isolates, London 2005-2006. Ann Clin Microbiol Antimicrob 2008; 7: 13. doi:10.1186/1476-0711-7-13 (Pubitemid 351935849)
7. Azap O, Arslan H, Serefhanoglu S, et al,. Risk factors for extended spectrum β-lactamase positivity in uropathogenic Esherichia coli isolated from community acquired urinary tract infections. Clin Microbiol Infect 2010; 16: 147-51
8. Laupland K, Church D, Vidakovich J, Mucenski M, Pitout J,. Community acquired extended spectrum β-lactamse producing Esherichia coli: importance of foreign travel. J Infect 2008; 57: 441-8
9. Livermore D, Hope R, Brick G, et al,. Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001-06. J Antimicrob Chemother 2008; 62 (Suppl. 2): ii41-54
10. Livermore D,. Advice on carbapenemase producers: recognition, infection control and treatment. Health Protection Agency 2011
11. Noordman P, Naas T, Poirel L,. Global spread of carbapenemase producing Enterobacteriaceae. Emerg Infect Dis 2011; 17: 1791-8
12. Yong D, Toleman M, Giske C, et al,. Characterisation of a new metallo-β-lactamase gene, blaNDM-1 and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 2009; 53: 5046-54
13. Kumarasamy K, Toleman M, Walsh T, et al,. Emergence of a new resistance mechanism in India, Pakistan, and the UK: a molecular, biological and epidemiological study. Lancet Infect Dis 2010; 10: 597-602
14. Walsh T, Weeks J, Livermore D, Toleman M,. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis 2011; 11: 355-62
15. Schwaber M, Carmeli Y,. Mortality and delay in effective therapy associated with extended spectrum β-lactamse production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 2007; 60: 913-20 (Pubitemid 47617735)